TAMPA, Fla., Nov. 6, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, November 13 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q3 2025. The Company will report its third quarter 2025 results on Wednesday after the market close.
Event: | Marpai 2025 Q3 Financial Results Conference Call |
Date: | November 13, 2025 |
Time: | 8:30 a.m. Eastern Time |
Call: | US: 1-646-357-8785 / Toll Free: 1-800-836-8184 |
Webcast: |
Follow us on X.com and LinkedIn
You may stream the call via the internet by following this link: The webcast replay will be available https://app.webinar.net/934VMynbB6a at the same URL within 2 hours of the end of the call. The replay of the call will be available within 2 hours of the end of the call until November 20, 2025 by calling 1-646-517-4150 or 1-888-660-6345 and entering the replay code, 79452 #.
About Marpai, Inc.
Marpai, Inc. (OTCQX: MRAI) is a technology platform company which operates subsidiaries that provide TPA, PBM and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $150 billion TPA sector serving self-funded employer health plans representing over $1.5 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://ir.marpaihealth.com.

| Last Trade: | US$1.13 |
| Daily Change: | 0.08 7.62 |
| Daily Volume: | 4,709 |
| Market Cap: | US$19.680M |
November 12, 2025 August 13, 2025 May 14, 2025 May 13, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load